接受长期去铁胺治疗患者的眼部变化。
Ocular changes in patients undergoing long-term desferrioxamine treatment.
作者信息
Arden G B, Wonke B, Kennedy C, Huehns E R
出版信息
Br J Ophthalmol. 1984 Dec;68(12):873-7. doi: 10.1136/bjo.68.12.873.
Abstract
In a group of young patients with thalassaemia and iron overload treated by subcutaneous infusions of desferrioxamine we have found a number of minor alterations in retinal function. The incidence of such changes is not related to drug dosage or to ferritin level but to abnormality of the extended glucose tolerance test.
摘要
在一组接受去铁胺皮下输注治疗的地中海贫血和铁过载的年轻患者中，我们发现视网膜功能存在一些轻微改变。这些变化的发生率与药物剂量或铁蛋白水平无关，而是与延长葡萄糖耐量试验异常有关。
相似文献
1
Ocular changes in patients undergoing long-term desferrioxamine treatment.接受长期去铁胺治疗患者的眼部变化。
Br J Ophthalmol. 1984 Dec;68(12):873-7. doi: 10.1136/bjo.68.12.873.
2
Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.地中海贫血患者中去铁胺导致的微量元素缺乏及急性眼毒性
Arch Dis Child. 1988 Mar;63(3):250-5. doi: 10.1136/adc.63.3.250.
3
Desferrioxamine-related ocular toxicity: a case report.去铁胺相关性眼部毒性：病例报告。
Indian J Ophthalmol. 2012 Jul;60(4):315-7. doi: 10.4103/0301-4738.98714.
4
Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine.一名中间型β地中海贫血患者长期接受去铁胺治疗后出现耳鸣。
Postgrad Med J. 1981 Sep;57(671):582-4. doi: 10.1136/pgmj.57.671.582.
5
Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
Med J Aust. 1987 Aug 17;147(4):177-9. doi: 10.5694/j.1326-5377.1987.tb133351.x.
6
Ocular findings in beta-thalassemia.β地中海贫血的眼部表现
Metab Pediatr Syst Ophthalmol (1985). 1990;13(1):23-5.
7
[The echocardiography in thalassemia major (author's transl)].重型地中海贫血的超声心动图检查（作者译）
Pediatr Med Chir. 1981 Mar-Jun;3(2-3):219-22.
8
Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.长期皮下注射去铁胺后重型地中海贫血患者的铁状态
Birth Defects Orig Artic Ser. 1988;23(5B):111-6.
9
Early iron overload in beta-thalassaemia major: when to start chelation therapy?重型β地中海贫血的早期铁过载：何时开始螯合治疗？
Arch Dis Child. 1982 Dec;57(12):929-33. doi: 10.1136/adc.57.12.929.
10
Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.长期大剂量皮下注射去铁胺疗法的眼毒性和耳毒性
Can J Ophthalmol. 1985 Jun;20(4):153-6.
引用本文的文献
1
Does thalassemia truly cause microvascular changes without us noticing? An optical coherence tomography angiography study of the children with beta-thalassemia.地中海贫血是否真的会在我们没有注意到的情况下引起微血管变化？一项针对β-地中海贫血儿童的光学相干断层扫描血管造影研究。
Int Ophthalmol. 2023 Oct;43(10):3755-3765. doi: 10.1007/s10792-023-02786-z. Epub 2023 Jun 30.
2
Use of Visual Electrophysiology to Monitor Retinal and Optic Nerve Toxicity.利用视觉电生理学监测视网膜和视神经毒性
Biomolecules. 2022 Sep 29;12(10):1390. doi: 10.3390/biom12101390.
3
Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major.铁螯合剂对重型地中海贫血患者眼功能的长期影响。
Clin Ophthalmol. 2021 May 20;15:2099-2109. doi: 10.2147/OPTH.S300974. eCollection 2021.
4
Retinal and Choriocapillaris Vascular Changes in Patients Affected by Different Clinical Phenotypes of β-Thalassemia: An Optical Coherence Tomography Angiography Study.β地中海贫血不同临床表型患者的视网膜和脉络膜毛细血管血管变化：一项光学相干断层扫描血管造影研究
Biology (Basel). 2021 Mar 28;10(4):276. doi: 10.3390/biology10040276.
5
Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies.β-地中海贫血患者的眼部异常：患病率、影响及管理策略。
Int Ophthalmol. 2020 Feb;40(2):511-527. doi: 10.1007/s10792-019-01189-3. Epub 2019 Oct 10.
6
Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature.接受去铁胺治疗患者的图案状营养不良：两例报告及文献复习
BMC Ophthalmol. 2018 Sep 12;18(1):246. doi: 10.1186/s12886-018-0911-2.
7
Comparison of contrast sensitivity in β-thalassemia patients treated by deferoxamine or deferasirox.接受去铁胺或地拉罗司治疗的β地中海贫血患者的对比敏感度比较。
J Optom. 2019 Jul-Sep;12(3):168-173. doi: 10.1016/j.optom.2018.01.002. Epub 2018 Mar 10.
8
Retinal nerve fiber layer thickness in children with β-thalassemia major.重型β地中海贫血患儿的视网膜神经纤维层厚度
Saudi J Ophthalmol. 2017 Oct-Dec;31(4):224-228. doi: 10.1016/j.sjopt.2017.10.001. Epub 2017 Oct 14.
9
Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients.用于早期检测重型β地中海贫血患者视网膜功能障碍的电生理评估
Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1349-1358. doi: 10.1007/s00417-017-3650-9. Epub 2017 Mar 30.
10
Retinal abnormalities in β-thalassemia major.重型β地中海贫血的视网膜异常
Surv Ophthalmol. 2016 Jan-Feb;61(1):33-50. doi: 10.1016/j.survophthal.2015.08.005. Epub 2015 Aug 29.
本文引用的文献
1
New clinical test of retinal function based upon the standing potential of the eye.基于眼静息电位的视网膜功能新临床测试。
Br J Ophthalmol. 1962 Aug;46(8):449-67. doi: 10.1136/bjo.46.8.449.
2
[Demonstration, by animal experiments, of the affinity of Desferal for iron].[通过动物实验证明去铁胺对铁的亲和力]
Schweiz Med Wochenschr. 1963 Jul 6;93:969-73.
3
Ferrioxamine excretion in iron-loaded man.
Blood. 1982 Aug;60(2):288-94.
4
Retinal abnormalities associated with anemia.与贫血相关的视网膜异常。
Arch Ophthalmol. 1983 Jul;101(7):1049-52. doi: 10.1001/archopht.1983.01040020051008.
5
An automated statis perimeter/adaptometer using light emitting diodes.一种使用发光二极管的自动静态视野计/自适应视野计。
Br J Ophthalmol. 1983 Jul;67(7):431-42. doi: 10.1136/bjo.67.7.431.
6
A modified ERG technique and the results obtained in X-linked retinitis pigmentosa.一种改良的视网膜电图技术及在X连锁视网膜色素变性中获得的结果。
Br J Ophthalmol. 1983 Jul;67(7):419-30. doi: 10.1136/bjo.67.7.419.
7
Desferrioxamine, ocular toxicity, and trace metals.
Lancet. 1983 Aug 27;2(8348):512-3. doi: 10.1016/s0140-6736(83)90537-8.
8
Ocular toxicity of high-dose intravenous desferrioxamine.大剂量静脉注射去铁胺的眼部毒性
Lancet. 1983 Jul 23;2(8343):181-4. doi: 10.1016/s0140-6736(83)90170-8.
9
An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload.正常受试者、缺铁患者及铁过载患者血清中铁蛋白的免疫放射分析。
J Clin Pathol. 1972 Apr;25(4):326-9. doi: 10.1136/jcp.25.4.326.
10
[Pathologic lens changes in experimental animals following continuous administration of high doses of Desferal].[连续高剂量给予去铁胺后实验动物的病理性晶状体变化]
Helv Physiol Pharmacol Acta. 1967;25(1):62-77.
Zotero 插件